This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005779/en/
Technavio has published a new market research report on the global glycated hemoglobin testing market from 2018-2022. (Graphic: Business Wire)
In this report, Technavio highlights the increased adoption of automation in diabetes care as one of the key emerging trends in the . In healthcare, the adoption of automation is increasing globally. Fully automated solutions lead to cost saving of staffing and can generate precise results. Automated solutions can also save the time of healthcare professionals as automation replaces manually intensive tasks. This allows researchers to devote an increased amount of time for patient consultation and precision in diagnosis. Advancements in technology have improved testing methods for diabetes as accurate, sensitive, and rapid outcomes methods are developed. As it reduces the chances of human error, automation improves productivity.
Automation also contributes to data-driven insights as the technology used to automate processes can deliver large volumes of data, which can be used to optimize and improve the performance of the tests. Automated systems collect data on the working of the process and use this information to improve the process. Such factors increase throughput and reduce the workload on healthcare professionals.
In this report, Technavio analysts highlight the rising incidence of diabetes and related conditions as a key factor contributing to the growth of the global glycated hemoglobin testing market:
Rising incidence of diabetes and related conditions
Growing adoption of a sedentary lifestyle and genetic manipulation causes type 1 or type 2 diseases. Globally, more than 400 million adults suffer from diabetes, out of which half of the incidences of diabetes remain undiagnosed. The early symptoms of type 2 diabetes are negligible, and people are often diagnosed after people have diabetes-related health complications such as hepatitis B, sleep apnea, and in some cases HIV. Diabetic patients undergoing HIV treatments may find it hard to control blood glucose levels. Therefore, effective diagnostic tools are in high demand to screen alarming levels of glucose.
According to a senior analyst at Technavio for , “Glycated hemoglobin testing is a good indicator of whether glucose levels are controlled The HbA1c test is one of the main ways in which type 2 diabetes is diagnosed. HbA1c tests may not be a preferred option for type 1 diabetes but are sometimes used with other tests.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Global glycated hemoglobin testing market segmentation
This market research report segments the global glycated hemoglobin testing market into the following key regions, including the Americas, APAC, and EMEA.
The Americas was the leading region for the in 2017, accounting for a market share of nearly 40%. By 2022, the Americas will continue dominating the market, whereas APAC and EMEA are expected to witness the highest growth.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005779/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES DIABETES
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/16/2018 09:07 AM/DISC: 05/16/2018 09:07 AM